1. Home
  2. CALC

as 06-05-2025 3:32pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Founded: 2011 Country:
United States
United States
Employees: N/A City: LA JOLLA
Market Cap: 26.7M IPO Year: N/A
Target Price: $16.33 AVG Volume (30 days): 27.8K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.53 EPS Growth: N/A
52 Week Low/High: $1.43 - $5.97 Next Earning Date: 05-14-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

CALC Daily Stock ML Predictions

Stock Insider Trading Activity of CalciMedica Inc. (CALC)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Bardin Stephen CALC Chief Financial Officer May 30 '25 Buy $1.69 1,000 $1,690.00 41,000

Share on Social Networks: